Uses of Irbepro 150

Irbepro 150 is an effective drug for patients with high blood pressure. The following article will describe more clearly the effects, side effects and notes when using this drug.

Irbepro 150 is used alone or together with other medicines to treat high blood pressure (hypertension). High blood pressure further increases the work of the heart and arteries. If maintained for a long time, the heart and arteries may not work properly. This can damage the blood vessels of the brain, heart, and kidneys, leading to stroke, heart failure, or kidney failure. Lowering blood pressure will reduce the risk of strokes and heart attacks.
Irbepro 150 is also used to treat high blood pressure with diabetic kidney disease. Diabetic nephropathy is a complication of type 2 diabetes that prevents the kidneys from working properly.
Irbepro 150 is an angiotensin II receptor blocker (ARB). It works by blocking a substance in the body that causes blood vessels to constrict. As a result, Irbepro 150 dilates blood vessels leading to a decrease in recorded blood pressure and an increase in blood and oxygen supply to the heart.
Irbepro dosage
Irbepro 150 can be taken with other antihypertensives and with or without food.
Hypertension
The recommended starting dose of Irbepro 150 is 150 mg once daily. The dose may be increased up to a maximum dose of 300 mg once daily if needed for better blood pressure control.
Kidney disease in patients with type 2 diabetes
The recommended dose is 300 mg once a day.
Patients with hyponatremia
Dosage adjustment in patients with hyponatremia
The recommended starting dose is 75 mg once daily in patients with intravascular hyponatremia (eg, patients with hyponatremia). are actively treated with diuretics or are on hemodialysis).

Use Irbepro 150 as directed by your doctor. Check the label on the medicine for more precise dosing instructions.
Take Irbepro 150 by mouth with or without food.
It is necessary to use Irbepro 150 according to its use schedule to receive its therapeutic benefits. Taking Irbepro 150 at the same time each day will help you remember the most.
Continue taking Irbepro 150 even if you feel stable. Do not forget to take any dose.
If you miss a dose of Irbepro, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your scheduled dosing schedule. Do not take 2 doses at the same time to make up for a missed dose.
Ask medical professionals any possible questions to better understand how to use Irbepro 150.
Contraindications to irbepro 150
Hypersensitivity to any ingredient of Irbepro.
Use in pregnancy: The use of angiotensin-II receptor antagonists (AIIRAs) is not recommended during the first trimester of pregnancy and is contraindicated in the second and third trimesters of pregnancy.
Evidence on teratogenic risk studies after exposure to ACE inhibitors during the first trimester of pregnancy is still inconclusive however, a small increase in risk cannot be ruled out.
Patients planning pregnancy should be changed to an alternative antihypertensive treatment with established safety for use during pregnancy. When pregnancy is diagnosed, treatment with Irbepro 150 should be discontinued immediately and, if appropriate, replacement therapy initiated.
Exposure to Irbepro 150 related therapy during the 2nd and 3rd trimesters is known to cause fetal toxicity (decreased kidney function, skull retardation) and neonatal toxicity. (renal failure, hypotension, hyperkalemia).
If exposure to Irbepro 150 occurs during the second trimester of pregnancy, ultrasound examination of fetal kidney and skull function is recommended.
Newborns whose mothers have received AIIRAs should be closely monitored for status. lower blood pressure.
Use during lactation:
As there is no information on the use of Irbepro 150 during lactation, Irbepro 150 is not recommended and safer alternative treatments are better established during breastfeeding is preferred, especially when nursing a newborn or premature baby.
It has not been studied whether Irbepro 150 or its metabolites are excreted in human milk. Currently available pharmacodynamic/toxicological data in rats indicate excretion of Irbepro 150 or its metabolites in milk.

What side effects can Irbepro 150 have?
Adverse effects in patients receiving Irbepro 150 are usually mild and transient.
As with other angiotensin II receptor antagonists, rare cases of hypersensitivity reactions (rash, urticaria, angioedema) have been reported.
Cases of cough have been reported very rarely with the use of Irbepro. The following have also been reported very rarely during post-administration monitoring:
Metabolic and nutritional disorders: Hyperkalemia. Nervous system disorders: Dizziness, headache. Ear and Cochlear Disorders: Tinnitus. Heart disorders: Tachycardia. Digestive disorders: Diarrhea, dyspepsia, nausea. Hepatobiliary disorders: Abnormal liver function, hepatitis. Musculoskeletal, connective tissue and bone disorders: Myalgia, arthralgia. Renal and urinary disorders: Impaired renal function includes some cases of renal failure in patients at risk.

Diuretics and other antihypertensives:
Other antihypertensives may enhance the antihypertensive effect of Irbepro, however, Irbepro 150 has been used safely with other antihypertensives. , eg β-blockers, long-acting calcium channel blockers, and thiazide diuretics. Pre-treatment with high-dose diuretics may lead to volume depletion and the risk of hypotension prior to initiation of Irbepro therapy.
Potassium supplements and potassium-sparing diuretics:
Based on experience with the use of other drugs that affect the renin-angiotensin system, concurrent use of a potassium-sparing diuretic, a tonic Potassium supplements, salt substitutes containing potassium, or other drugs that may increase serum potassium levels (eg, heparin) may lead to increased serum potassium and are therefore not recommended.
Lithium: Reversible increases in serum lithium levels and toxicity have been reported with concomitant use of lithium with ACE inhibitors. Similar effects have rarely been reported with Irbepro.